Table 2.
Treatment-related toxicities in patients who started treatment (n = 38)
| Adverse event | Grade 1, 2 (%) | Grade 3 (%) | Grade 4 (%) |
|---|---|---|---|
| Anemia | 7 (18) | 3 (8) | |
| Chills | 2 (5) | ||
| Fatigue | 13 (34) | 2 (5) | |
| Fever | 3 (8) | 1 (3) | |
| Gait disturbance | 2 (5) | ||
| Limb edema | 3 (8) | ||
| Acneiform rash | 3 (8) | ||
| Maculo-papular rash | 2 (5) | ||
| Constipation | 2 (5) | ||
| Dry mouth | 2 (5) | ||
| Oral mucositis | 2 (5) | ||
| Nausea | 8 (21) | 1 (3) | |
| Vomiting | 8 (21) | ||
| Ileal obstruction | 1 (3) | ||
| Allergic reaction | 2 (5) | ||
| Alanine aminotransferase Increase | 4 (11) | ||
| Alkaline phosphatase Increase | 5 (13) | 1 (3) | |
| Aspartate aminotransferase Increase | 10 (26) | 1 (3) | |
| Bilirubin increase | 3 (8) | ||
| Creatinine increase | 3 (8) | ||
| Lymphocyte count decrease | 2 (5) | 1 (3) | |
| Neutrophil count decrease | 3 (8) | 1 (3) | |
| Platelet count decrease | 10 (26) | 2 (5) | |
| Weight loss | 3 (8) | ||
| White blood cell decrease | 4 (11) | ||
| Anorexia | 5 (13) | 1 (3) | |
| Myalgia | 2 (5) | ||
| Generalized muscle weakness | 3 (8) | ||
| Headache | 4 (11) | ||
| Peripheral motor neuropathy | 2 (5) | ||
| Peripheral sensory neuropathy | 4 (11) | ||
| Cough | 3 (8) | ||
| Epistaxis | 3 (8) | 1 (3) | |
| Hypoxia | 1 (3) | ||
| Muscle weakness lower limb | 1 (3) | ||
| Dehydration | 2 (3) | ||
| Investigations: Other, specify | 1 (3) | 1 (3) | |
| Urinary tract infection | 1 (3) | ||
| Upper respiratory infection | 1 (3) | ||
| Diarrhea | 1 (3) | ||
| Blurred vision | 1 (3) | ||
| Total worst degree | 20 (58) | 11 (16) | 0 (0) |
Includes specific adverse events with at least two grade 1 or 2 events or 1 grade 3 event. Total worst degree includes all treatment-related adverse events.